ALIMTA 100 MG — DIN 02306433
PEMETREXED (PEMETREXED DISODIUM) : 100 MG · ELI LILLY CANADA INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ALIMTA?
ALIMTA 100 MG contains PEMETREXED (PEMETREXED DISODIUM) : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02306433, held by ELI LILLY CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 29-Jan-2026. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ALIMTA used for?
Malignant pleural mesothelioma (with cisplatin); Initial treatment of nonsquamous NSCLC (with cisplatin); Maintenance or second-line treatment of nonsquamous NSCLC (monotherapy).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Pemetrexed cost around the world?
Pemetrexed is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Italy | ex-factory (classe H) | 15 | 24 | EUR███.██ |
| Saudi Arabia | public | 14 | 20 | SAR███.██ |
| Greece | producer price (ex-factory) | 18 | 18 | EUR███.██ |
| Romania | max producer price | 13 | 17 | RON███.██ |
| South Africa | single exit price | 17 | 17 | ZAR███.██ |
| United Kingdom | hospital | 13 | 13 | GBP███.██ |
| Hungary | producer price (ex-factory) | 7 | 12 | HUF███.██ |
| Australia | ex-manufacturer | 5 | 10 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 3 | 7 | CZK███.██ |
| Slovakia | categorised final price | 3 | 7 | EUR███.██ |
| Bahrain | retail (max) | 4 | 5 | BHD███.██ |
| Iceland | max wholesale | 2 | 4 | ISK███.██ |
| Morocco | PPV (public price) | 1 | 3 | MAD███.██ |
157 pack listings across 115 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Pemetrexed pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Pemetrexed in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Pemetrexed, across 36 DINs, of which 14 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ACCORD HEALTHCARE INC | 3 | 3 | PEMETREXED DISODIUM FOR INJECTION, PEMETREXED FOR INJECTION | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 3 | 3 | TARO-PEMETREXED | Sourceable in Canada |
| AURO PHARMA INC | 3 | 2 | PEMETREXED DISODIUM FOR INJECTION | Sourceable in Canada |
| EUGIA PHARMA INC. | 3 | 2 | PEMETREXED DISODIUM FOR INJECTION | Sourceable in Canada |
| DR REDDY'S LABORATORIES LTD | 2 | 2 | PEMETREXED FOR INJECTION, USP | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 2 | PEMETREXED DISODIUM FOR INJECTION | Sourceable in Canada |
| ACTAVIS PHARMA COMPANY | 3 | 0 | ACT PEMETREXED | No marketed DIN |
| PFIZER CANADA ULC | 3 | 0 | PEMETREXED DISODIUM FOR INJECTION | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 3 | 0 | PEMETREXED DISODIUM FOR INJECTION | No marketed DIN |
| APOTEX INC | 2 | 0 | PEMETREXED | No marketed DIN |
| ELI LILLY CANADA INC | 2 | 0 | ALIMTA | No marketed DIN |
| MARCAN PHARMACEUTICALS INC | 2 | 0 | PEMETREXED DISODIUM FOR INJECTION, PEMETREXED DISODIUM FOR INJECTION USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 100 mg or 500 mg pemetrexed per vial. |
| Storage | Store at 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Pemetrexed |
|---|---|
| ATC code | L01BA04 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02306433 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2306433 |
| Brand name | ALIMTA |
| Generic / active ingredient | PEMETREXED (PEMETREXED DISODIUM) : 100 MG |
| Market authorization holder | ELI LILLY CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | L01BA04 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01BA |
| Current status | CANCELLED POST MARKET |
| Status date | 29-Jan-2026 |
| Original market date | 2009-01-09 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
500 mg/m2 as an IV infusion over 10 minutes every 21 days. Must supplement with folic acid, vitamin B12, and dexamethasone. Cisplatin is co-administered for certain indications.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to pemetrexed or any ingredient in the formulation; concomitant yellow fever vaccine.
Warnings and precautions
Should be administered under supervision of a physician experienced in cancer chemotherapy. Bone marrow suppression is the dose-limiting toxicity. Risk of hepatotoxicity and renal failure.
Is Pemetrexed in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by EUGIA PHARMA INC., last seen 30 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
14 of 36 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PEMETREXED DISODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02438674 |
| PEMETREXED DISODIUM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | 02528754 |
| PEMETREXED DISODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | 02528746 |
| PEMETREXED DISODIUM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02438682 |
| PEMETREXED DISODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | 02459434 |
| PEMETREXED DISODIUM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02517647 |
| PEMETREXED DISODIUM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | 02394227 |
| PEMETREXED DISODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02517639 |
| PEMETREXED FOR INJECTION | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02515423 |
| PEMETREXED FOR INJECTION, USP | 500 MG | POWDER FOR SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | 02463091 |
2 · Same class — other molecules in ATC L01BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Methotrexate | ACH-METHOTREXATE · APO-METHOTREXATE · EUGIA-METHOTREXATE · EUGIA-METHOTREXATE TABLETS · JAMP METHOTREXATE TABLETS · JAMP-METHOTREXATE · M-METHOTREXATE · METHOTREXATE · METHOTREXATE DBL INJ 10MG/ML · METHOTREXATE DBL INJ 2.5MG/ML · METHOTREXATE DBL INJ 25MG/ML · METHOTREXATE INJECTION BP · METHOTREXATE INJECTION USP · METHOTREXATE INJECTION, BP · METHOTREXATE INJECTION, USP · METHOTREXATE PF/SA INJECTION · METHOTREXATE SOD INJ 25MG/ML USP · METHOTREXATE SODIUM INJ 20MG · METHOTREXATE SODIUM INJ 25.0MG/ML · METHOTREXATE SODIUM INJ 25MG/ML · METHOTREXATE SODIUM INJ 25MG/ML USP · METHOTREXATE SODIUM INJECTION · METHOTREXATE SODIUM INJECTION USP · METHOTREXATE TAB 2.5MG · METHOTREXATE TAB 2.5MG USP · METHOTREXATE TABLETS, USP · METHOTREXATE-LIQ IM IV IAR INT IVR 25MG/ML · METHOTREXATE-PWS IM IV IAR INT IVR 20MG/VIAL · METOJECT · PENTA-TAMOXIFEN TABLETS · PMS-METHOTREXATE · RATIO-METHOTREXATE SODIUM · RHEUMATREX TAB 2.5MG | 51 | 20 | Yes |
| Pemetrexed | ACT PEMETREXED · ALIMTA · PEMETREXED · PEMETREXED DISODIUM FOR INJECTION · PEMETREXED DISODIUM FOR INJECTION USP · PEMETREXED FOR INJECTION · PEMETREXED FOR INJECTION, USP · TARO-PEMETREXED | 36 | 14 | Yes |
| Pralatrexate% | FOLOTYN | 2 | 1 | Yes |
| Raltitrexed | TOMUDEX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01BC | Azacitidine · Capecitabine · Cytarabine · Decitabine · Decitabine, Combinations · Fluorouracil · Fluorouracil, Combinations · Gemcitabine · Trifluridine, Combinations | 112 | 34 |
| L01BB | Cladribine · Clofarabine · Fludarabine · Mercaptopurine · Nelarabine · Tioguanine | 18 | 10 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ALIMTA called?
The same molecule, Pemetrexed, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Pemetrexed Ever Pharma | Latin | Australia, Czechia, Saudi Arabia |
| Pemetrexed Accord | Latin | Australia, Iceland |
| Pexitrex | Latin | Saudi Arabia |
| ARMISARTE | Latin | Czechia |
| Pemetrexed EPC | Latin | Saudi Arabia |
| PEMETREXED EUGIA | Latin | Australia |
| PEMETREXED FRESENIUS KABI | Latin | Czechia |
| PEMETREXED KOANAA | Latin | Bahrain |
| Pemetrexed Seacross | Latin | Saudi Arabia |
| Pemetrexed SUN | Latin | Australia |
| Pemetrexed W&H | Latin | Iceland |
| Pemetrexed-AFT | Latin | Australia |
| Alix | Latin | Saudi Arabia |
| ALMETRA | Latin | Saudi Arabia |
| jodaxed | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.